Pancreatic Cancer Research

ResearcherHospital of the University of PennsylvaniaActive in the last 2 years

Bryson W. Katona

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8186-9119; OpenAlex author ID A5035166264. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
102
Papers, trials and grants by year

2020: 1 paper · 2021: 6 papers · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 8 papers · 2026: 1 paper

Papers 26

  1. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  2. The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. Co-author DOI 10.1002/cncr.35666↗
  3. Assessment of barriers to pancreatic cancer surveillance in high-risk individuals. Last author DOI 10.1002/jgc4.70117↗
  4. Current Approaches of Pancreatic Cancer Surveillance in High-Risk Individuals. Last author DOI 10.1007/s12029-025-01184-1↗
  5. Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Last author DOI 10.1097/mpa.0000000000002483↗
  6. Challenges of early detection of pancreatic cancer. Last author DOI 10.1172/jci191942↗
  7. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  8. Improving uptake of germline genetic testing amongst individuals at high-risk of pancreatic ductal adenocarcinoma. First author DOI 10.21037/tgh-24-152↗
  9. A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals. Co-author DOI 10.3390/cancers17111866↗
  10. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  11. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Last author DOI 10.1007/s10689-024-00392-1↗
  12. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  13. Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review. Last author DOI 10.1093/bjsopen/zrad023↗
  14. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  15. Assessment of the Psychosocial Impact of Pancreatic Cancer Surveillance in High-Risk Individuals. Last author DOI 10.3390/cancers16010086↗
  16. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  17. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  18. Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations. Last author DOI 10.18632/genesandcancer.223↗
  19. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28127↗
  20. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  21. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  22. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001835↗
  23. EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-21-0161↗
  24. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter Co-author DOI 10.1158/1940-6207.capr-21-0233↗
  25. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28099↗
  26. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adeno… Co-author DOI 10.1158/1078-0432.ccr-19-3313↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Randall E. Brand · 9 shared papers, 2021–2026 · strength 1.35
  2. Fay Kastrinos · 8 shared papers, 2021–2026 · strength 1.06
  3. Aimee Lee Lucas · 6 shared papers, 2021–2026 · strength 0.92
  4. Diane M. Simeone · 5 shared papers, 2021–2026 · strength 0.79
  5. Beth Dudley · 3 shared papers, 2021–2025 · strength 0.72
  6. James J. Farrell · 5 shared papers, 2021–2024 · strength 0.65
  7. Elena M. Stoffel · 5 shared papers, 2021–2024 · strength 0.65
  8. Thomas Charles King · 3 shared papers, 2022–2026 · strength 0.59
  9. Jessica N. Everett · 4 shared papers, 2021–2026 · strength 0.56
  10. Sonia S. Kupfer · 4 shared papers, 2021–2026 · strength 0.56
  11. Salvatore Paiella · 4 shared papers, 2021–2026 · strength 0.56
  12. George Zogopoulos · 4 shared papers, 2021–2026 · strength 0.56
  13. Susan M. Domchek · 3 shared papers, 2021–2025 · strength 0.55
  14. Louise L. Wang · 2 shared papers, 2022–2024 · strength 0.54
  15. Marcia Irene Canto · 4 shared papers, 2021–2024 · strength 0.51
  16. Michael Goggins · 4 shared papers, 2021–2024 · strength 0.51
  17. Raymond Couric Wadlow · 3 shared papers, 2023–2026 · strength 0.48
  18. Anil K. Rustgi · 4 shared papers, 2021–2024 · strength 0.48
  19. Daniel C. Chung · 4 shared papers, 2021–2024 · strength 0.47
  20. Norma Alonzo Palma · 2 shared papers, 2025–2026 · strength 0.45
  21. Lisa A. Ford · 2 shared papers, 2025–2026 · strength 0.45
  22. Erica L. Carpenter · 4 shared papers, 2020–2022 · strength 0.44
  23. Rosalie C. Sears · 3 shared papers, 2021–2026 · strength 0.44
  24. Michael J. Shen · 1 shared paper, 2025 · strength 0.42
  25. Melissa Heller · 1 shared paper, 2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.